Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2012

View Archived Issues

Scientists discover new biomarker of oral squamous cell carcinoma

RNAi screen identifies targets for diseases involving protein misfolding

Alnylam provides update on pipeline goals for 2012

Achillion provides new clinical data on protease inhibitors for hepatitis C

Spanish study reveals novel potential biomarker of CCL

Phase III data disclosed on Technosphere Insulin versus usual care for diabetes

Novartis discovers new pan-Trk kinase inhibitor

Novo Nordisk presents new analogues of fibroblast growth factor 21

Korean university researchers disclose novel glycolipid derivatives

Pfizer prepares new agents for hepatitis C virus infection

Evotec achieves milestone for oncology product from Boehringer Ingelheim

Phase I study of CB-625 scheduled to begin this quarter

NovoMedix patents new eIF4E inhibitors for cancer

Novel chemokine CCR2 receptor antagonists synthesized by Janssen Pharmaceutica

DFH Pharma and NCI enter collaboration

Hospira kicks off enrollment in phase III program of biosimilar EPO

Sinovac begins phase III study of EV 71 vaccine

New leptin fusion proteins patented by AngioChem

Polaris begins dosing in ADI-PEG 20/docetaxel combination study

FDA clears Immuron's IND for phase IIb study in NASH/fatty liver

Dosing starts in phase IIa study of Pharmos' levotofisopam

Companies to collaborate on shark antibody technology

Hemispherx receives extension to modify NDA

Intercell and SSI announce start of phase II trial of tuberculosis vaccine candidate

Starpharma reaches agreement with FDA on phase III VivaGel studies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.